08.13.10
After three years of research and development, Kappa BioSciences has launched a new form of vitamin K2 MK-7. The company’s proprietary technology will initially be used to produce menaquinone or vitamin K2 MK-7 for the human nutrition market in Europe and North America. Dr. Egil Greve, CEO, will direct the global operation from the company’s headquarters in Oslo, Norway.
Responding to customer requests Kappa also successfully focused on developing an assay and quality testing method for vitamin K2 MK-7, which is exclusive among producers. This allows customers to independently verify they are receiving the K2 MK-7 they are paying for, as well as confirm label claims.
Kappa will market its novel, all-trans vitamin K product under the trade name K2VITAL and will have both powder and oil forms to offer formulators. With a growing body of science confirming new and positive health benefits from vitamin K supplementation, interest in vitamin K has increased significantly in the past several years.
The company intends to launch additional products across its broad market reach in the future.
Responding to customer requests Kappa also successfully focused on developing an assay and quality testing method for vitamin K2 MK-7, which is exclusive among producers. This allows customers to independently verify they are receiving the K2 MK-7 they are paying for, as well as confirm label claims.
Kappa will market its novel, all-trans vitamin K product under the trade name K2VITAL and will have both powder and oil forms to offer formulators. With a growing body of science confirming new and positive health benefits from vitamin K supplementation, interest in vitamin K has increased significantly in the past several years.
The company intends to launch additional products across its broad market reach in the future.